AbbVie gets option on early Argenx cancer drug for $40 million
 

AbbVie gets option on early Argenx cancer drug for $40 million
(Reuters) - AbbVie has acquired an option on an early-stage immu**-oncology drug from biotech company Argenx, giving the U.S. drugmaker access to a treatment with the potential to block a biological pathway that allows cancers to grow.http://feeds.feedburner.com/~ff/reut...?d=yIl2AUoC8zA http://feeds.feedburner.com/~ff/reut...NE:F7zBnMyn0Lo http://feeds.feedburner.com/~ff/reut...NE:V_sGLiPBpWU
http://feeds.feedburner.com/~r/reute...~4/MOVuneev4hk